Sermorelin Therapy

Sermorelin acts on the GHRH receptors of the anterior pituitary gland, stimulating somatotroph cells to synthesize and release growth hormone in a physiologically natural pulsatile pattern. Because it relies on the pituitary's own capacity to produce GH, it preserves the hypothalamic-pituitary feedback loop that regulates hormone levels. This mechanism means the body's own regulatory systems prevent excessive GH production, maintaining a safer physiological range. The resulting increase in growth hormone subsequently promotes hepatic production of IGF-1, which mediates many of the metabolic, restorative, and body composition effects associated with optimal GH levels.

Sermorelin is frequently the first growth hormone peptide recommended to patients who are new to peptide therapy, due to its established clinical history. Adults in their 40s through 60s experiencing the typical signs of GH decline, including increased body fat, reduced muscle tone, decreased energy, and poor sleep, are the most common candidates. Patients who prefer a conservative and well-documented approach to GH optimization often gravitate toward Sermorelin over newer peptides.

Sermorelin is administered via subcutaneous injection, typically given before bedtime to coincide with the natural nocturnal GH surge. Daily injections are the most common protocol, with treatment courses typically lasting three to six months. Some practitioners use a five-days-on, two-days-off schedule to maintain pituitary sensitivity.